Article Contents ::
- 1 The Brand Name REVOLADE Has Generic Salt :: ELTROMBOPAG
- 2 REVOLADE Is From Company GSK Priced :: Rs. 13265
- 3 REVOLADE have ELTROMBOPAG is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name REVOLADE Has Generic Salt :: ELTROMBOPAG
REVOLADE Is From Company GSK Priced :: Rs. 13265
REVOLADE have ELTROMBOPAG is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| ELTROMBOPAG | TAB | Rs. 13265 | 7 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 7 |
| REVOLADE | GSK | 50MG(ELTROMBOPAG FREE ACID) | 7 | Rs. 13265 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From GSK :: REVOLADE | ELTROMBOPAG | #N/A | #N/A |
Indications for Drugs ::
Adult chronic immune (idiopathic) thrombocytopenic purpura (ITP), Hepatitis C Virus (HCV) related Thrombocytopenia.
Drug Dose ::
Adult Initially 50 mg once daily. East Asian patient 25 mg once daily. Then, adjust dose to maintain platelet count >50,000/microliter. Max: 75 mg daily. Should be taken on an empty stomach.Take at least 4 hr before or after antacids, dairy products or other Ca-containing food products or mineral supplements containing polyvalent cations. After adjustment, platelet counts should be monitored at least weekly for 2-3 weeks. Wait for at least 2 weeks to see the effect of any dose adjustment on the patient’s platelet response prior to considering another dose adjustment. Renal Impairment: No dose adjustment is necessary in ITP patients with renal impairment. Hepatic Impairment: Should not be used in ITP patients with liver cirrhosis (hepatic impairment unless the expected benefit outweighs the identified risk of portal venous thrombosis.
Contraindication ::
Eltrombopag is contraindicated in patients with severe hepatic impairment and who are hypersensitive to any of its excipients.
Drug Precautions ::
Not established for use in other thrombocytopenic conditions. Regularly monitor clinical haematology, platelet counts & serum liver test throughout therapy. Renal & hepatic impairment; hepatic disease. Thrombotic/thromboembolic complications. Increased risk of bleeding upon discontinuation of treatment. Bone marrow reticulin formation & risk of bone marrow fibrosis. Malignancies & progression of malignancies. Pregnancy & lactation. Childn <18 yr, elderly. Drug Side Effects ::
Insomnia; headache, paraesthesia; cataract, dry eye; nausea; GI & hepatobiliary disorders; rash, pruritus, alopecia; arthralgia, myalgia, muscle spasm, bone pain; fatigue, peripheral oedema; thromboembolic events.
Pregnancy category ::
3
Drug Mode of Action ::
Small-molecule thrombopoietin (TPO)-receptor agonist that interacts with human TPO receptor transmembrane domain of human TPO-receptor & initiates signaling cascades that induce proliferation & differentiation of megakaryocytes from bone marrow progenitor cells.
Drug Interactions ::
Increased plasma Cmax & AUC of HMG-CoA reductase inhibitors. Caution w/ methotrexate, topotecan. Increased conc w/ fluvoxamine; decreased conc w/ rifampicin & lopinavir/ritonavir. Reduced absorption by antacids, dairy products & other products containing polyvalent cations (eg Fe, Ca, Mg, Al, Se, Zn). Reduced plasma AUC & Cmax w/ high-calorie & -fat meal. Monitor platelet counts when used in combination w/ lopinavir/ritonavir & other drugs for treatment of idiopathic thrombocytopenic purpura (ITP).
